Nevanimibe
Nevanimibe (PD-132301) is an orally active and selective acyl-coenzyme A:cholesterol O-acyltransferase 1 (ACAT1) inhibitor with an EC50 of 9 nM. Nevanimibe inhibits ACAT2 with an EC50 of 368 nM. Nevanimibe induces cell apoptosis and has the potential for adrenocortical cancer[1].
Product Specifications
CAS Number
133825-80-6
Product Name Alternative
PD-132301; ATR-101
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Acyltransferase; Apoptosis
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Nevanimibe.html
Purity
98.99
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NCC1(C2=CC=C(N(C)C)C=C2)CCCC1)NC3=C(C(C)C)C=CC=C3C(C)C
Molecular Formula
C27H39N3O
Molecular Weight
421.62
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
ACAT1; ACAT2
Citation 01
Cell Rep. 2022 Nov 29;41 (9) :111724.|Mol Cell Endocrinol. 2024 Dec 1:594:112385.|Structure. 2021 Dec 2;29 (12) :1410-1418.e4.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
GRL-0496, SARS-CoV-2 chymotrypsin-like protease (3CLpro, Mpro, Nsp5) inhibitor
